Stock Track | XTALPI Soars 5.18% Intraday After Reporting First Full-Year Profit and 201% Revenue Growth

Stock Track03-26

XTALPI's stock surged 5.18% during intraday trading on Thursday, following the release of its full-year 2025 financial results which showed the company's first annual profit and significant revenue growth.

The AI for Science (AI4S) leader reported revenues of RMB802.6 million for 2025, representing a year-over-year increase of 201.2%. The company achieved a net profit of RMB134.6 million, marking its first full year of profitability since listing. XTALPI also reported a strong cash balance of RMB7,068.6 million as of December 31, 2025.

The company's Drug Discovery Solutions business saw revenue surge 418.9% to RMB537.9 million, driven by expansion of its antibody business and progression of service-enabled pipelines. XTALPI has secured multiple strategic collaborations with global pharmaceutical companies and expanded into new therapeutic areas including peptides, molecular glues, and nucleic acids.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120663565?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 09:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120663565","market":"sg","top_or_hot":-1,"title":"Stock Track | XTALPI Soars 5.18% Intraday After Reporting First Full-Year Profit and 201% Revenue Growth","media":"Stock Track","content":"<p>XTALPI's stock surged 5.18% during intraday trading on Thursday, following the release of its full-year 2025 financial results which showed the company's first annual profit and significant revenue growth.</p><p>The AI for Science (AI4S) leader reported revenues of RMB802.6 million for 2025, representing a year-over-year increase of 201.2%. The company achieved a net profit of RMB134.6 million, marking its first full year of profitability since listing. XTALPI also reported a strong cash balance of RMB7,068.6 million as of December 31, 2025.</p><p>The company's Drug Discovery Solutions business saw revenue surge 418.9% to RMB537.9 million, driven by expansion of its antibody business and progression of service-enabled pipelines. XTALPI has secured multiple strategic collaborations with global pharmaceutical companies and expanded into new therapeutic areas including peptides, molecular glues, and nucleic acids.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | XTALPI Soars 5.18% Intraday After Reporting First Full-Year Profit and 201% Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | XTALPI Soars 5.18% Intraday After Reporting First Full-Year Profit and 201% Revenue Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-26 09:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>XTALPI's stock surged 5.18% during intraday trading on Thursday, following the release of its full-year 2025 financial results which showed the company's first annual profit and significant revenue growth.</p><p>The AI for Science (AI4S) leader reported revenues of RMB802.6 million for 2025, representing a year-over-year increase of 201.2%. The company achieved a net profit of RMB134.6 million, marking its first full year of profitability since listing. XTALPI also reported a strong cash balance of RMB7,068.6 million as of December 31, 2025.</p><p>The company's Drug Discovery Solutions business saw revenue surge 418.9% to RMB537.9 million, driven by expansion of its antibody business and progression of service-enabled pipelines. XTALPI has secured multiple strategic collaborations with global pharmaceutical companies and expanded into new therapeutic areas including peptides, molecular glues, and nucleic acids.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02228","symbol_name":"晶泰控股","start_time":0,"source_url":"","article_id":"1120663565","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120663565","pubTimestamp":1774489051,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"XTALPI's stock surged 5.18% during intraday trading on Thursday, following the release of its full-year 2025 financial results which showed the company's first annual profit and significant revenue...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02228":"晶泰控股"},"translate_title":"个股追踪|XTALPI盘中大涨5.18%公布首次全年盈利营收增长201%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02228":1},"content_text":"XTALPI's stock surged 5.18% during intraday trading on Thursday, following the release of its full-year 2025 financial results which showed the company's first annual profit and significant revenue growth.The AI for Science (AI4S) leader reported revenues of RMB802.6 million for 2025, representing a year-over-year increase of 201.2%. The company achieved a net profit of RMB134.6 million, marking its first full year of profitability since listing. XTALPI also reported a strong cash balance of RMB7,068.6 million as of December 31, 2025.The company's Drug Discovery Solutions business saw revenue surge 418.9% to RMB537.9 million, driven by expansion of its antibody business and progression of service-enabled pipelines. XTALPI has secured multiple strategic collaborations with global pharmaceutical companies and expanded into new therapeutic areas including peptides, molecular glues, and nucleic acids.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120663565","isCrawlerRequest":true}